Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsTOPICALStandard

AKLIEF

TRIFAROTENE

Standard Dose
0.005%
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary

Approval overview AKLIEF is listed in Drugs@FDA under application 211527 (NDA).

Review priority: STANDARD Marketing status: Prescription Active ingredient TRIFAROTENE Form and strength CREAM;TOPICAL - 0.005% Sponsor GALDERMA LABS LP Submission history Latest submission status date: 2022-07-19 00:00:00.

Structured Monograph

Clinical summary

Approval overview AKLIEF is listed in Drugs@FDA under application 211527 (NDA). Review priority: STANDARD Marketing status: Prescription Active ingredient TRIFAROTENE Form and strength CREAM;TOPICAL - 0.005% Sponsor GALDERMA LABS LP Submission history Latest submission status date: 2022-07-19 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.